MedTrace Logo

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

NCT04245722 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2023-10-26

No results posted yet for this study

Summary

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

Interventions

DRUG

FT596

Experimental Interventional Therapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

Rituximab

Monoclonal Antibody

DRUG

Obinutuzumab

Monoclonal Antibody

DRUG

Bendamustine

Conditioning agent

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2023-09-27
Completion
2023-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04245722 on ClinicalTrials.gov